DRUG CONJUGATES COMPRISING ANTIBODIES AGAINST CLAUDIN 18.2

The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 06. März Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

SAHIN UGUR [VerfasserIn]
TÜRECI ÖZLEM [VerfasserIn]
WALTER KORDEN [VerfasserIn]
KREUZBERG MARIA [VerfasserIn]
MITNACHT-KRAUS RITA [VerfasserIn]
LE GALL FABRICE [VerfasserIn]
JACOBS STEFAN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-03-06, Last update posted on www.tib.eu: 2024-04-23, Last updated: 2024-04-26

Patentnummer:

EP4331578

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA001395424